Life Sciences Times, Author at Boston Life Sciences Times

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

Study Links Tumor Metabolism to Drug Binding Behavior in Live Cancer Cells

December 9, 2025

THIS WEEK'S STORIES

Vyome Reports Positive Phase 2 Results for VT-1953, Plans Pivotal Study for FDA Approval

December 8, 2025

PepGen Names Joseph Vittiglio, Esq., Chief Business and Legal Officer

December 8, 2025

Byron Jobe Named One of Modern Healthcare’s 100 Most Influential People in Healthcare

December 8, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Acadia Pharmaceuticals Wins FDA Approval for DAYBUE STIX Powder Formulation for Rett Syndrome

ImmunityBio Wins EMA Recommendation for Conditional Approval of ANKTIVA With BCG for Bladder Cancer

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

Innoviva Specialty Therapeutics Reports Lancet Publication of Positive Phase 3 Data for Zoliflodacin in Gonorrhea

EDITOR PICKS

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

Study Links Tumor Metabolism to Drug Binding Behavior in Live Cancer Cells

THIS WEEK'S STORIES

Vyome Reports Positive Phase 2 Results for VT-1953, Plans Pivotal Study for FDA Approval

PepGen Names Joseph Vittiglio, Esq., Chief Business and Legal Officer

Byron Jobe Named One of Modern Healthcare’s 100 Most Influential People in Healthcare

POPULAR CATEGORY

ABOUT US

FOLLOW US